Literature DB >> 8080311

Clinical benefits of high and variable sodium concentration dialysate in hemodialysis patients.

B M Jenson, S A Dobbe, D P Squillace, J T McCarthy.   

Abstract

Twenty-one hemodialysis patients were studied during 25 dialysis sessions with a dialysate sodium of 140 mEq/L and during 25 sessions with a high and variable sodium dialysate (145 mEq/L decreased to 140 mEq/L). Bicarbonate dialysate and ultrafiltration-controlled dialysis equipment were used. Neither the average interdialytic weight gain nor the predialysis and postdialysis blood pressures changed. The need for 5% saline infusions decreased from 168 + 137 ml/patient to 2 + 6 ml/patient for 25 dialyses. Use of 0.9% saline boluses remain unchanged. Fewer dialysis sessions required the use of the Trendelenburg position (p < .02) or a decrease in the transmembrane pressure (p < .05). With the use of high and variable sodium dialysate concentration, patients had less symptomatic hypotension (p < .05) and fewer symptoms of dialysis dysequilibrium, such as cramps or nausea.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080311

Source DB:  PubMed          Journal:  ANNA J        ISSN: 8750-0779


  2 in total

1.  Sodium modelling to reduce intradialytic hypotension during haemodialysis for acute kidney injury in the intensive care unit.

Authors:  Katherine E Lynch; Fatimah Ghassemi; Jennifer E Flythe; Mengling Feng; Marzyeh Ghassemi; Leo Anthony Celi; Steven M Brunelli
Journal:  Nephrology (Carlton)       Date:  2016-10       Impact factor: 2.506

2.  Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Authors:  Joanna Leigh Dunlop; Alain Charles Vandal; Janak Rashme de Zoysa; Ruvin Sampath Gabriel; Imad Adbi Haloob; Christopher John Hood; Philip James Matheson; David Owen Ross McGregor; Kannaiyan Samuel Rabindranath; David John Semple; Mark Roger Marshall
Journal:  BMC Nephrol       Date:  2013-07-15       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.